Kornimate/medical-research-clean huggingface dataset:
prevention of nosocomial infections (cleankids)

Conditions: Severe Acute Malnutrition; Health Care Associated Infection; Multi Drug Resistant Organisms

Summary: while the standardization of treatment protocols for severe acute malnutrition (sam) has helped to reduce historically high mortality, mortality in inpatient settings remains substantial, likely due to the severity of complications associated with late presentation and health-care associated infection (hcai). the purpose of this study is to serve as an important stand-alone description to inform the understanding of the magnitude of the problem and help guide implementation of measures to reduce the risk of nosocomial infection and multi-drug resistance.

this study is designed as a cross-sectional, non-randomized, two-site, four-phase study: an initial baseline period, two intervention periods, and a final interruption period. this is a descriptive study to collect information on the risk of hcais in the msf-supported inpatient nutritional treatment centers. information on key clinical indicators will be collected regularly according to the routine program procedures from the time of admission to discharge. all children will undergo a blood draw for culture at time of admission and at the time of any suspected hospital-acquired bloodstream infection. as part of active surveillance for bacterial colonization, including multi-drug resistant organisms, all children will undergo nasal and rectal swabs at the time of admission, suspected infection, and discharge. data will provide an estimate of nosocomial infection incidence under routine circumstances and inform sample size calculations if further study is warranted.

Eligibility criteria:
inclusion criteria: 1. 6 to 59 months old 2. severe acute malnutrition with medical complications 3. parent / caregiver signing written informed consent exclusion criteria: 1. health condition that does not allow blood draw 2. contraindication to the use of soap or chlorhexidine gluconate, as recommended by the product 3. refusal to discontinue the use of skin care products that are incompatible with chlorhexidine gluconate according to the product's directions for use
a study to evaluate an updated dexamethasone intravitreal (into the eye) applicator in adult participants with macular edema due to diseases of the retina

Conditions: Macular Edema

Summary: the dexamethasone posterior segment drug delivery system (dex ps dds) applicator is used to deliver an implant with medicine to the eye. abbvie is updating the dex ps dds applicator. this purpose of this study is to show that the updated dex ps dds applicator works in adult participants with macular edema due to retinal diseases. the dex ps dds is approved for the treatment of macular edema. participants will be placed into 1 of 2 groups, called treatment arms. each group receives the same treatment drug delivered using different applicators. around 54 adult participants with macular edema will be enrolled in the study in approximately 7-10 sites in the united states. participants will receive a single intravitreal (into the eye) administration of dex ps dds implant using either the currently-approved dex ps dds applicator or the the updated applicator. the participants will be observed for a duration of 7 days, with the dex ps dds implant received on day 1 and follow-up through day 7. the updates being evaluated in this study are related to the dex ps dds applicator only, with the safety and efficacy of the dex ps dds implant well characterized and the same as the currently marketed product. participants will attend regular visits during the study at a hospital or clinic. the applicator function will be checked by medical assessment, checking for side effects, procedural complications and/or product complaints, and evaluating the administration procedure.


Eligibility criteria:
inclusion criteria: - participants with macular edema due to retinal vein occlusion (branch retinal vein occlusion or central retinal vein occlusion) or diabetic macular edema. exclusion criteria: - participants with ocular conditions in the study eye for which dexamethasone posterior segment drug delivery system implant is contraindicated.

Keywords: macular edema dexamethasone branch retinal vein occlusion central retinal vein occlusion diabetic macular edema noninfectious uveitis ozurdex dexamethasone posterior segment drug delivery system (dex ps dds)
recurrent hypoglycemia in type 1 diabetes (aim 1)

Conditions: Diabetes Mellitus, Type 1

Summary: this study will explore the cerebral mechanisms of impaired awareness of hypoglycemia (iah) in type 1 diabetics following exposure to experimental recurrent hypoglycemia (hg). to induce iah, patients with t1d identified to have normal awareness of hypoglycemia (nah) will undergo three 2-hour long hypoglycemic clamps. neurochemical profiles will be measured by high field mrs before and after induction of iah. subject glycemic variability for 2 weeks and activity/sleep for 1 week before each study will be monitored as all factors have been shown to alter responses to hg.

the long-term goal of this project is to identify how recurrent hypoglycemia (hg) leads to the clinical syndrome of impaired awareness of hypoglycemia (iah) in type 1 diabetes (t1d). this study will test the hypothesis that recurrent hg in t1d leads to an upregulation in brain glucose transport and alterations in glutamatergic and gabaergic tone. the investigators will use mrs methodology that permits evaluation of cerebral cortex and hypothalamus in the same session to simultaneously evaluate the cerebral correlates/mediators of impaired awareness and impaired counterregulatory hormone responses (crr). high mr data quality and reproducibility will be ensured by using high field mr scanners and technical advances (automated voxel placement, real-time voxel position, frequency, shim updates). continuous glucose monitoring and actigraphy will be used to chronicle glucose variability and activity/exercise/sleep in the weeks before each experiment to assess the impact of these variables on iah.

Eligibility criteria:
inclusion criteria: * type 1 diabetes diagnosed on clinical or laboratory grounds * diabetes duration 2 - 30 years * hemoglobin a1c \<8.5% exclusion criteria: * impaired awareness of hypoglycemia as determined by the cox and gold questionnaires * pregnant or plan to become pregnant during the study period * uncontrolled hypertension (blood pressure \> 145/95 mmhg at screening) * evidence of autonomic neuropathy (presence of orthostatic hypotension or history of gastroparesis) * proliferative retinopathy * impaired kidney function (gfr \< 45) * history of myocardial infarction, stroke, seizures, neurosurgical procedures, major depression requiring hospitalization within the last 5 years, arrhythmias * current substance abuse * use of drugs that can alter glucose metabolism including but not limited to glucocorticoids and niacin, and excluding insulin and glucose lowering drugs used to treat diabetes, as determined by a clinician * inability to undergo mri scanning, including but not limited to unable to remain still in an mri scanner for more than 30 minutes, claustrophobia, presence of paramagnetic substances or pacemakers in body, weight over 300 lbs
efficacy of a nurse-based, anesthesiologist-supervised acute pain service for pediatric patients

Conditions: Postoperative Pain; Satisfaction

Summary: can a nurse-based, anesthesiologist-supervised model reduce prevalence of postoperative pain in pediatric patients?

comparison of 2 treatment model in reducing prevalence of postoperative pain in pediatric patients: conventional model(c): nurses give fixed-dose analgesic according to surgeons' prescription study model(s): nurses give initial-dose analgesic according to surgeons' prescription. in case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.

Eligibility criteria:
inclusion criteria: * age up to15 years old * underwent surgery with moderate to severe pain exclusion criteria: * ent, eye, ambulatory surgery * cardiac, neurosurgery * severe neurocognitive impairment * continuous epidural analgesia which anesthesiologists take care by themselves

Keywords: nurse-based, acute pain service, pediatric, postoperative, pain
quadratus lumborum block : effect on acute pain and quality of recovery after laparoscopic adrenalectomy

Conditions: Pain Management; Nerve Block; Laparoscopic Adrenalectomy

Summary: this prospective, randomized ,control study aims to compare the analgesic effect,quality of recovery, length of hospital stay ,et al. between single-injection qlb(quadratus lumborum block)+general anesthesia (ga) and general anesthesia (ga) alone in patients undergoing laparoscopic adrenalectomy.


Eligibility criteria:
inclusion criteria: * age 18-70 yrs * american society of anesthesiologists physical statusⅰ-ⅲ * undergo laparoscopic adrenalectomy * informed consent exclusion criteria: * a known allergy to the drugs being used * coagulopathy, on anticoagulants * analgesics intake, history of substance abuse * participating in the investigation of another experimental agent * inability to properly describe postoperative pain to investigators (eg, language barrier, neuropsychiatric disorder)
evaluation of the safety of lubiprostone in pediatric participants aged ≥ 6 years to < 18 years with functional constipation

Conditions: Constipation - Functional

Summary: a study of the safety of lubiprostone in pediatric participants aged ≥ 6 years to \< 18 years diagnosed with functional constipation.

to assess the long-term safety and tolerability of oral lubiprostone 12 or 24mcg capsules dosed twice daily (bid) when administered orally for 24 weeks in pediatric participants with functional constipation. evaluation of lubiprostone safety and tolerability is the primary objective in this study.

Eligibility criteria:
inclusion criteria: * medically-confirmed diagnosis of functional constipation per rome iii diagnostic criteria for childhood functional constipation * at least 6 years of age but less than 18 years of age at the time of randomisation * only stable dose of selective serotonin re-uptake inhibitors (ssris), serotonin-specific reuptake inhibitor (snris), or monoamine oxidase inhibitors (mao) inhibitors are allowed if participant is taking antidepressants exclusion criteria: * any gastrointestinal (gi) condition, other than constipation, affecting gi motility or defecation * untreated faecal impaction at the time of screening * medical/surgical condition that might interfere with the absorption, distribution, metabolism, or excretion of the study medication
an observational study of mircera (methoxy polyethylene glycol-epoetin beta) in anemic patients with chronic kidney disease (norm)

Conditions: Anemia

Summary: this observational, prospective, multi-centre, single-arm study will evaluate the efficacy of mircera (methoxy polyethylene glycol-epoetin beta) in patients with chronic kidney disease previously on treatment with short-acting epoetin alpha. data will be collected for 6 months.


Eligibility criteria:
inclusion criteria: * adult patients, age 18 years or above * chronic kidney disease (ckd) with anemia * patients on dialysis receiving short-acting epoetin (epo) * serum ferritin level \>/=100 ng/ml or transferrin saturation (tsat) \>/=20% exclusion criteria: * patients unwilling to give informed consent * uncontrolled hypertension * transfusion of red blood cells within 8 weeks of the start of mircera treatment * relevant acute or chronic bleeding history * hemolysis * hemoglobinopathies * pure red cell aplasia
atmospheric pressure and epistaxis relationship

Conditions: Atmospheric Pressure; Adverse Effect; Epistaxis Nosebleed

Summary: in this study, investigators aim to understand the relationship between changes in atmospheric pressure and blood pressure, and to investigate whether these changes have an impact on the etiology of epistaxis.

this study aims to investigate the potential effects of changes in atmospheric pressure on epistaxis and, if such effects exist, to review treatment adjustments based on weather forecasts for hypertensive patients to prevent potential hypertensive emergencies and enhance patient comfort. this research poses no risk to patients and is purely observational and clinical in nature. the study will be conducted prospectively over a period of 6 months at the emergency department of ankara etlik city hospital, focusing on patients presenting with epistaxis.after initial evaluation upon presentation to the emergency department, patients will undergo routine emergency department monitoring for epistaxis, including physical examination, vital sign monitoring, evaluation of coagulation parameters, and hemoglobin levels. apart from routine tests, no additional invasive or non-invasive procedures will be performed by us. data obtained from patients and daily atmospheric pressure parameters will be evaluated and analyzed.

Eligibility criteria:
inclusion criteria: patients aged 18 and above presenting to the emergency department with complaints of epistaxis, whether active or resolved. willing volunteers consenting to participate in the study. residing in central districts of ankara exclusion criteria: patients under the age of 18. pregnant individuals. those with a history of maxillofacial surgery. patients reporting a history of trauma at the time of admission. patients stating they are from a city other than ankara.

Keywords: atmospheric pressure epistaxis blood pressure
message framing for telephone quitline callers

Conditions: Smoking; Nicotine Dependence

Summary: the purpose of this study is to compare gain-framed counseling + gain-framed materials" to standard care quitline counseling + standard print materials. the investigators hypothesize that gain-framed counseling + gain-framed materials group will produce higher abstinence rates than standard care counseling and standard care information. the data in this study will be used to determine effect size estimates for a large scale study.

this pilot study is meant to be translational (i.e., positive study results could easily translate to the actual practices of the nys smokers' quitline) - as much as possible, the standard practices of the quitline will be followed. in this context, a randomized pilot clinical trial comparing exclusively "gain-framed counseling + gain-framed materials" to standard care quitline counseling + standard print materials will be conducted with individuals calling the nys smokers' quitline for assistance in quitting smoking. following assessment of eligibility and informed consent, 2,500 smokers will be assisted by specialists in either the yc or sc experimental conditions. consistent with the current practices of the quitline, following the counseling intervention, participants will be mailed a package containing print materials encouraging smoking cessation, and participants eligible for nicotine replacement therapy (nrt) will receive a 2-week supply of nicotine replacement medication. consistent with quitline practices, all callers will be required to set a "quit date" within 2 weeks of their initial call. a quitline specialist will initiate a follow-up call approximately 10 to 14 days after the print materials and nrt has been mailed. for callers receiving nrt, the manufacturer's suggested course of therapy (e.g., 8 weeks of nrt) will be recited to callers, and quitline specialists will suggest that callers use the money they save from not smoking to purchase additional nrt and/or that they check with their insurance carrier to see if additional nrt would be covered. participants will be assessed before receiving the gain-framed counseling + gain-framed materials or standard care counseling, immediately after receiving counseling, approximately 1 week after their quit date for those who receive nrt, and at a 3-month follow-up to see if the gain-framed counseling + gain-framed materials participants, as predicted, are more likely to promote smoking cessation. several brief measures that assess potential mediator of treatment will be administered.

Eligibility criteria:
inclusion criteria: * adults (18+ years) * new york state residents * english-speaking * current smokers who utilize quitline services seeking quitting assistance for themselves exclusion criteria: * callers who are enrolled in the proactive program for medicaid/uninsured clients, or special programs through their insurance company or county

Keywords: smoking tobacco message framing
effects of traumeel®s tablets on recovery and inflammatory immune response after repeated bouts of exercise

Conditions: Exercise-induced Muscle Soreness

Summary: to investigate and compare the effects of traumeel®s tablets versus placebo on recovery and inflammatory immune response over a period of 72 hours after a second bout of strenuous concentric exercise on bicycle (exercise #2).


Eligibility criteria:
inclusion criteria: * sex: male * age ≥ 18 and ≤ 40 years * bmi ≥ 18.5 and \< 27,5 kg/m2 (who standard for normal range bmi) * maximum relative oxygen uptake (vo2max) \< 53 ml/kg x min * general state of good health * non-smoker * medically approved unrestricted participation in sports as shown by diagnostic performance test conducted on treadmill no longer than 3 months prior to study entry * willingness to provide signed informed consent exclusion criteria: * weekly training volume ≥ 6 hours * use of dietary supplements (incl. high-dosed vitamins and minerals) * chronic immune deficiency * current infection * heart and/or circulation disorders * abnormal findings on exercise ecg * musculoskeletal disorders * any current clinical condition that requires systemic treatment or might have an impact on study objectives * hypersensitivity to botanicals of the compositae family (e.g. echinacea) * lactose intolerance * illicit drug or alcohol abuse * participation in another clinical trial within 4 weeks prior to study entry

Keywords: muscle exercise soreness damage traumeel homeopathy
the optimal intervention time of radiotherapy for oligometastatic stage iv non-small cell lung cancer（nsclc）

Conditions: Oligo-metastatic Stage IV Non-small Cell Lung Cancer

Summary: this study evaluates the optimal intervention time of radiotherapy for oligometastatic stage iv lung cancer.


Eligibility criteria:
inclusion criteria: * 18 to 75 years old , male or female * pathologically or cytologically proven oligometastatic stage iv nsclc non-small cell lung cancer（nsclc） * primary tumors can be measured * distant organ metastases number ≤ 5 * karnofsky score \>70,zubrod performance status 0-1 * estimated life expectancy of at least 12 weeks * reproductive age women should ensure that before entering the study period contraception * hemoglobin≥10.0g/dl,wbc≥ 4000 cells/mm³,platelet count≥100,000 cells/mm³ * aspartate aminotransferase (ast) and alanine aminotransferase (alt) \< 2.5 times upper limit of normal,bilirubin normal * creatinine normal or creatinine clearance ≥ 60 ml/min * patients have good compliance to treatment and follow-up of acceptance. exclusion criteria: * allergic to pemetrexed, cisplatin, docetaxel and contrast medium * distant metastases organs \> 5 * the primary tumor or lymph node already received surgical treatment (except for biopsy) * patient who received radiotherapy for primary tumor or lymph node * patient who received the the epidermal growth factor targeted therapy * patient who received chemotherapy or immunotherapy * patient who suffered from other malignant tumor * patient who have taken other drug test within 1 month * pregnant woman or lactating women and women in productive age who refuse to take contraception in observation period * subject with a severe allergic history or idiosyncratic * subject with severe pulmonary and cardiopathic disease history * refuse or incapable to sign the informed consent form of participating this trial * drug abuse or alcohol addicted * subject with a personality or psychiatric diseases, people with no legal capacity or people with limited capacity for civil conduct

Keywords: intervention time radiotherapy oligometastatic non-small cell lung cancer
evaluation of systane ultra lubricant eye drops

Conditions: Dry Eye

Summary: to evaluate the safety and efficacy of two artificial tears in dry eye patients.


Eligibility criteria:
inclusion criteria: * documented diagnosis of dry eyes * must not have worn contact lenses for 1 week preceding enrollment exclusion criteria: * age related
evaluation of individual health coaching sessions provided by a patient expert as part of therapeutic education for patients registered at the chronic pain consultation

Conditions: Chronic Pain

Summary: chronic pain is defined as a persistent sensory and emotional experience, lasting for more than three months, and often resistant to treatment. it can result from various conditions, including life-threatening diseases, accidents, or therapeutic procedures like surgery or chemotherapy. chronic pain significantly impacts a patient's physical and psychological well-being, often leading to body image issues and functional deterioration in daily activities, both at home and at work or school. the world health organization recognized chronic pain as a disease in 2019. chronic pain patients must adapt to their condition, acquiring new skills and knowledge through therapeutic education. group sessions, a key part of therapeutic education, help break the isolation felt by many patients, fostering shared experiences and mutual support. since 2015, the saint-joseph hospital's chronic pain consultation has offered group education workshops, inspired by those at the pitié-salpêtrière hospital in paris. however, many patients struggle to apply new skills independently after these workshops. in response, individualized coaching was introduced in 2020. this approach, led by a health coach who is also an expert patient, provides personalized support to help patients set and achieve realistic goals, fostering active engagement in their lives through tailored strategies and ongoing support. the main aim of this pilot study is to assess the quantitative and qualitative contribution of personalized support by an "expert patient" chronic pain coach (individual coaching), on the functional and emotional impact and emotional impact of their pain, in patients followed up in a chronic pain consultation and having group therapeutic education workshops.


Eligibility criteria:
inclusion criteria: * patient aged ≥ 18 years * patients followed in chronic pain consultations referred to the therapeutic education workshops * patient affiliated with a health insurance plan * french-speaking patient * patient capable of giving oral, informed, and explicit consent exclusion criteria: * patient with psychiatric disorders making inclusion in group workshops impossible * patient unwilling to participate in individual coaching sessions patient under guardianship or curatorship patient deprived of liberty patient under legal protection pregnant or breastfeeding patient